Curtiss-Wright heads into June with its ORTEX stock score at a six-month peak and the share price up 18% from its April lows — yet the Street's analyst consensus remains firmly at Hold, with targets already trailing the current price.
The valuation re-rating is the most interesting tension in the setup right now. The ORTEX composite stock score has climbed to 83, driven by a sharp jump in the value pillar from around 32 to 44 in mid-May. That move reflects improving earnings yield and a pullback in EV/EBIT toward 41. Yet the trailing P/E now runs near 47x, and the forward EV/EBITDA is around 32x — multiples that leave the stock priced for continued execution. The dividend yield signal is historically strong, ranking in the 99th percentile, but the actual yield is negligible at sub-0.2%, making it more of a quality marker than an income story. EPS momentum is positive but modest, scoring 57 on the 30-day measure, and forward EPS growth ranks only in the 25th percentile year-on-year — a reminder that the premium is being paid for quality and defense exposure, not explosive growth.
The analyst picture is one where targets keep chasing the stock higher without conviction changing. Citigroup raised its target to $775 on May 18, from $728 — notable as the most recent move and the first to approach the current price of $747.61. Stifel lifted to $723 back in April. Both firms have been raising targets consistently since late 2025, yet neither has budged from Hold or Neutral. The consensus mean target of $788 implies only modest return potential from here. Bulls point to the Q1 print — 14% EPS growth to $3.40, Defense Electronics revenue up 17.5% year-on-year, and raised full-year guidance to 10-11% revenue growth with strong free cash flow conversion. Bears counter with order timing risk: $50 million in orders slipped out of Q3 2025 due to continuing resolution uncertainty, and revenue recognition under percentage-of-completion accounting adds further unpredictability. The Street's collective posture is best described as respectful but cautious — they keep upgrading the target, not the rating.
Short positioning does not add much drama to this story. Short interest is running at roughly 1.7% of the free float, up about 16% over the past month in absolute share terms — a gradual rebuild, but from a very low base. Days to cover is 2.4 on the official FINRA data. Borrowing costs are minimal at 0.40% annualised. Availability is essentially unconstrained — the lending pool is deep and untapped, which means there is no squeeze dynamic in play and no meaningful friction for anyone looking to add or unwind short exposure. The ORTEX short score of 30.4, ranking in the 65th percentile, reflects the slow drift higher in SI rather than any aggressive short-side buildup. Options are similarly quiet: the put/call ratio of 1.03 is barely above its 20-day average of 1.01, a z-score of just 0.16. Positioning across the borrow and options markets looks neutral rather than charged.
Peer performance this week sharpens the relative story. MRCY surged 15.9% on the week and ATI added 9.2%. ATRO rose 8.9%. CW's 2.2% weekly gain looks measured against that backdrop — closer in spirit to HWM, which was effectively flat. The contrast matters: CW is the higher-multiple, higher-quality name in the peer group, and its relative steadiness in a week when some defense names moved sharply suggests institutional holders are sitting tight rather than rotating.
Insider activity through the 90-day window runs net positive in share terms at roughly 7,446 shares, but that figure is entirely shaped by the March 17 cluster — the CEO, CFO, COO, and four other executives all sold on the same day, with Chair and CEO Lynn Bamford alone clearing $2.2 million. The more recent May 27 EVP sale of 220 shares at $752.91 is routine by comparison. The net figure overstates positive conviction; the March cluster looks like scheduled plan activity, and there has been no material buying to offset it.
The next earnings event is scheduled for August 5. Between now and then, the watch points are whether Defense Electronics order flow recovers cleanly from the Q3 2025 CR-related slippage, and whether the valuation premium — built on consistent execution — holds as the P/E multiple approaches its upper range.
See the live data behind this article on ORTEX.
Open CW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
